Dr. Harald Nusser has been leading Novartis Access since June 2015. Since October 2016, he has also taken on the responsibility for the newly formed unit, Novartis Social Business. Dr. Nusser started his career at Schering AG in 2000 as a mathematician in the global research and development function. Having worked in both exploratory research as well as clinical research, he held positions of increasing responsibility between 2004 and 2010 in Corporate Strategy and Strategic Planning in both Schering AG and as of 2006 in Bayer in various senior positions. He is also a member of the Novartis Access to Medicines Committee.
Most companies want their corporate responsibility programs to work, but few develop the evidence base to understand whether they actually do. Experts weigh in on how to achieve social change at scale.
A new independent policy study, commissioned by Novartis, reveals controversial views about what African experts think is the best way to push forward progress on malaria eliminations. This guest column details the biggest findings of the Malaria Futures for Africa, or MalaFA study, and explains why we need to take advantage of these African insights and learnings.
Health systems in lower-income countries must now cope with the new epidemic of chronic diseases without losing focus of the ongoing fight against infectious diseases, asserts Harald Nusser, global head at Novartis Access, in this #Access2Meds guest column.